Premium
Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft
Author(s) -
Sottnik J. L.,
Hansen R. J.,
Gustafson D. L.,
Dow S. W.,
Thamm D. H.
Publication year - 2011
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2010.00240.x
Subject(s) - osteosarcoma , vegf receptors , cancer research , medicine , oncology
The purpose of this study was to determine the impact of the non‐steroidal anti‐inflammatory drug tepoxalin on canine tumour cell growth and describe the changes associated with tepoxalin treatment. In vitro experiments were performed to assess tepoxalin‐associated alterations in tumour cell growth. Clinically achievable tepoxalin concentrations did not significantly alter tumour cell growth in vitro . Vascular endothelial growth factor (VEGF) production and hypoxia‐inducible factor‐1 α dose‐dependently increased in vitro in the presence of tepoxalin. A canine osteosarcoma xenograft was used to determine in vivo effects of tepoxalin on tumour growth and angiogenesis. Despite increased VEGF in vitro , there was a significant growth delay associated with tepoxalin treatment. Normal dogs were administered tepoxalin to assess effects on systemic VEGF production, but not found to have significantly increased VEGF. These data suggest that tepoxalin may moderately inhibit tumour growth and may be administered as an analgesic to tumour‐bearing dogs.